Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Looking at its longer-term performance, Eli Lilly's stock appreciated by 422.93% over the past five ... considering the ...

The stock carries a hefty premium, but it is justified by the company's growth and the size of the market for GLP-1s. Eli Lilly's Q1 report ... maintaining its revenue forecast of $58 billion ...

The company missed its earnings per share (EPS) forecast, reporting $3.34 against an expected $3.46. The market reacted negatively, with Eli Lilly’s stock dropping 8.56% in pre-market trading.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

While maintaining its revenue forecast ... Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t ...

Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings. The company's 2025 outlook disappointed investors, however, leading to the decline. The stock ...